GlaxoSmithKline plc (GSK) Receives GBX 1,578.50 Consensus Price Target from Brokerages

GlaxoSmithKline plc (LON:GSK) has received a consensus recommendation of “Hold” from the twenty-two research firms that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is GBX 1,578.50 ($21.41).

GSK has been the topic of a number of analyst reports. Beaufort Securities restated a “buy” rating and set a GBX 1,800 ($24.41) target price on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Liberum Capital reiterated a “buy” rating and issued a GBX 1,760 ($23.87) price target on shares of GlaxoSmithKline in a research note on Wednesday, October 25th. Goldman Sachs Group reiterated a “buy” rating and issued a GBX 1,900 ($25.77) price target on shares of GlaxoSmithKline in a research note on Tuesday, October 17th. Jefferies Group boosted their price target on shares of GlaxoSmithKline from GBX 1,675 ($22.71) to GBX 1,700 ($23.05) and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, set a GBX 1,925 ($26.11) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Thursday, October 26th.

In other news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($17.77), for a total value of £262,000 ($355,302.41). Also, insider Urs Rohner bought 473 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.59) per share, for a total transaction of £7,180.14 ($9,737.10). Over the last 90 days, insiders bought 502 shares of company stock worth $756,702.

GlaxoSmithKline (LON GSK) traded up GBX 9.20 ($0.12) on Friday, hitting GBX 1,364.40 ($18.50). 8,193,834 shares of the company were exchanged, compared to its average volume of 8,130,000. GlaxoSmithKline has a 52 week low of GBX 1,270 ($17.22) and a 52 week high of GBX 1,724.50 ($23.39). The stock has a market cap of $67,650.00 and a PE ratio of 2,842.50.

GlaxoSmithKline (LON:GSK) last released its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The company had revenue of GBX 784.30 billion for the quarter.

The firm also recently announced a dividend, which was paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th were issued a GBX 19 ($0.26) dividend. The ex-dividend date was Thursday, November 9th. This represents a dividend yield of 1.41%.

WARNING: “GlaxoSmithKline plc (GSK) Receives GBX 1,578.50 Consensus Price Target from Brokerages” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://weekherald.com/2018/02/15/glaxosmithkline-plc-gsk-receives-gbx-1578-50-consensus-price-target-from-brokerages.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply